N/A
Completed N=380
An Audit of Patients With Crohn's Disease Treated With Infliximab (P06066)
Source: ClinicalTrials.gov NCT00988832 ↗Enrolled (actual)
380
Serious AEs
9.5%
Results posted
Jul 2012
Primary outcomePrimary: Mean Cost Per Participant of Consultations With Health Care Providers (HCPs) — 913.48; 962.30; 1317.58; 1664.45 Pounds sterling per participant — p=<0.0001
Summary
The aim of this study is to quantify how infliximab therapy is being used in the UK and the consequent impact on health care resources, which will help to inform budget holders and payers on the costs associated with the treatment of Crohn's Disease.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Cost Per Participant of Consultations With Health Care Providers (HCPs) |
913.48; 962.30; 1317.58; 1664.45 | <0.0001 sig |
| PRIMARY Mean Cost Per Participant of Elective Surgical Procedures |
752.46; 572.75; 818.46; 1078.47 | 0.0004 sig |
| PRIMARY Mean Cost Per Participant Due to Non-elective/Emergency Inpatient Admissions |
1107.65; 769.95; 1002.33; 1261.42 | 0.0041 sig |
| PRIMARY Mean Cost Per Participant for Admissions for Day Case Surgery |
48.73; 18.60; 33.16; 48.13 | 0.0423 sig |
| PRIMARY Mean Cost Per Participant for All Hospitalizations |
1908.85; 1361.30; 1853.95; 2388.01 | 0.0006 sig |
| PRIMARY Mean Cost Per Participant of Accident and Emergency (A&E) Visits |
3.01; 4.34; 6.60; 8.22 | 0.0014 sig |
| PRIMARY Mean Cost Per Participant for Crohns-related Medications |
327.98; 431.78; 653.31; 879.05; 327.98; 615.23 | — |
| PRIMARY Mean Cost Per Participant for Diagnostic Tests During Planned Outpatient Consultations |
411; 199.77; 303.94; 380.08 | <0.0001 sig |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of Crohn's Disease.
- Over the age of 18 years.
- Must have received the first infusion of infliximab on or after 1st January 2003 (when the maintenance therapy license was granted).
- Must have received at least one infusion of infliximab.
- A minimum of 12 months data prior to, and 24 months data post infliximab exposure should be available in the medical records.
- Must have been under the care of the participating center for the entirety of the study period.
Exclusion Criteria
- Should not have been involved in any clinical trial during the observational period (ie, a minimum of 12 months before and 24 months after first receiving infliximab).
- Should not have received any biologic therapy prior to infliximab.
Data sourced from ClinicalTrials.gov (NCT00988832). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.